- Home
- RXRX vs SNDX Comparison
RXRX vs SNDX Comparison
Compare RXRX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | SNDX |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RXRX | SNDX |
|---|---|---|
| Price | $3.80 | $18.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $7.50 | ★ $38.69 |
| AVG Volume (30 Days) | ★ 14.2M | 1.3M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.79 | 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | $74,681,000.00 | ★ $172,352,000.00 |
| Revenue This Year | $12.11 | $107.19 |
| Revenue Next Year | $82.52 | $41.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 26.92 | ★ 627.84 |
| 52 Week Low | $2.77 | $8.59 |
| 52 Week High | $7.18 | $25.59 |
Technical Indicators
Market Signals| Indicator | RXRX | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 35.45 |
| Support Level | $2.85 | $14.91 |
| Resistance Level | $3.99 | $22.40 |
| Average True Range (ATR) | 0.23 | 0.85 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 90.28 | 8.28 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.